NTLA vs. BMY
Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NTLA or BMY.
Performance
NTLA vs. BMY - Performance Comparison
Returns By Period
In the year-to-date period, NTLA achieves a -53.53% return, which is significantly lower than BMY's 16.30% return.
NTLA
-53.53%
-32.78%
-45.27%
-49.61%
-1.10%
N/A
BMY
16.30%
6.73%
34.48%
17.37%
3.75%
2.81%
Fundamentals
| NTLA | BMY | |
|---|---|---|
| Market Cap | $1.70B | $115.20B |
| EPS | -$5.45 | -$3.58 |
| PEG Ratio | -0.10 | 1.96 |
| Total Revenue (TTM) | $43.09M | $47.44B |
| Gross Profit (TTM) | $35.51M | $33.40B |
| EBITDA (TTM) | -$521.07M | $5.03B |
Key characteristics
| NTLA | BMY | |
|---|---|---|
| Sharpe Ratio | -0.73 | 0.61 |
| Sortino Ratio | -0.91 | 1.16 |
| Omega Ratio | 0.90 | 1.14 |
| Calmar Ratio | -0.49 | 0.36 |
| Martin Ratio | -1.60 | 1.51 |
| Ulcer Index | 28.39% | 11.52% |
| Daily Std Dev | 61.60% | 28.64% |
| Max Drawdown | -92.10% | -70.62% |
| Current Drawdown | -91.98% | -23.83% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Correlation
The correlation between NTLA and BMY is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Risk-Adjusted Performance
NTLA vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NTLA vs. BMY - Dividend Comparison
NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.23%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.23% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% | 3.31% |
Drawdowns
NTLA vs. BMY - Drawdown Comparison
The maximum NTLA drawdown since its inception was -92.10%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY. For additional features, visit the drawdowns tool.
Volatility
NTLA vs. BMY - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 29.23% compared to Bristol-Myers Squibb Company (BMY) at 13.66%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NTLA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities